
GLP-1 medications — Ozempic (semaglutide), Wegovy (semaglutide), Saxenda (liraglutide), and Mounjaro (tirzepatide) — have become a regular topic in Singapore weight-management consultations. The most common first question isn't "will it work" but "what does it actually cost?". This 2026 update sets out what to expect on the monthly bill, why prices vary between sources, and how supply, dosing, and subsidies factor in.
GLP-1 medications — Ozempic (semaglutide), Wegovy (semaglutide), Saxenda (liraglutide), and Mounjaro (tirzepatide) — have become a regular topic in Singapore weight-management consultations. The most common first question isn't "will it work" but "what does it actually cost?". This 2026 update sets out what to expect on the monthly bill, why prices vary between sources, and how supply, dosing, and subsidies factor in.
A note on numbers: pricing for GLP-1 medications in Singapore varies meaningfully between clinics, pharmacies, telemedicine platforms, and over time as supply normalises. The ranges below are typical for early 2026 — your actual price depends on dose, clinic, and brand. Treat them as a planning estimate, not a quote.
For all four medications, the cost is meaningfully higher in the titration phase than at a steady maintenance dose — you'll be told to step up the dose every 4 weeks for the first 3–5 months, and each step usually costs more.
Most GLP-1s are titrated up over 3–5 months. Higher maintenance doses cost more — usually because the manufacturer prices stepwise by dose strength, and because the higher-dose pens contain more drug.
Different clinics apply different margins on top of the wholesale price. Specialist endocrinology and weight-management clinics in central locations often price higher; subscription-based telemedicine platforms aiming for predictable monthly pricing often sit in the middle of the range.
For semaglutide, the only branded products on the Singapore market are Novo Nordisk's Ozempic (diabetes label) and Wegovy (weight-management label). There is no generic semaglutide in Singapore as of early 2026. "Compounded" semaglutide marketed by some overseas pharmacies is not HSA-approved and should not be assumed to be quality-controlled for Singapore use.
Global semaglutide and tirzepatide supply has fluctuated since 2023. Where supply is tight, prices nudge upward and waitlists become more common. Singapore supply situations are best checked with the prescriber at the time of consultation rather than from a static guide.
Medisave coverage for GLP-1s in Singapore is limited and condition-specific. For type 2 diabetes management under the Chronic Disease Management Programme (CDMP), GLP-1 medications such as Ozempic may be partly Medisave-claimable at participating providers — but this is the diabetes use, not the weight-management use. For weight management as the primary indication, Medisave does not generally apply.
MediShield Life covers in-patient costs and selected outpatient treatments; it does not typically cover outpatient GLP-1 prescriptions for weight management. Some Integrated Shield Plan (IP) rider add-ons cover specific outpatient prescriptions — check your specific plan, as coverage varies considerably.
CHAS subsidies apply to consultations and selected medications at participating clinics for eligible conditions. Weight-management GLP-1s are typically not in the CHAS subsidy scope.
Some employer health insurance plans in Singapore cover obesity treatment, including GLP-1 medications. This is uneven across employers and worth checking with your HR/benefits team if you have group cover.
For most men in Singapore considering GLP-1 medication for weight management, the practical choice is between a specialist or GP clinic with in-person visits, and a telemedicine platform with online consults and home delivery. The medication itself costs roughly the same; the difference is in consultation fees, follow-up structure, and convenience.
The cost question is downstream of the clinical question. A doctor will usually consider GLP-1 medication when:
A first consultation will usually include a discussion of side-effect expectations — nausea, slow gastric emptying, and the importance of titrating dose carefully — and a plan for the first 12 weeks.
Sometimes, at lower doses. The active drug is the same (semaglutide); the difference is the licensing (diabetes vs weight management) and the dose strengths available. Wegovy is licensed specifically for weight management at higher doses, which is why total cost at maintenance can be higher.
Importing prescription medication for personal use into Singapore is tightly controlled by HSA. Counterfeit and compounded semaglutide is a real safety concern globally. Pricing in Singapore reflects HSA-regulated supply chains, not just markup.
For most people using GLP-1 medication for weight management, stopping is associated with weight regain. This is a long-term treatment for a chronic metabolic condition rather than a short course. Cost planning should reflect that.
On average, GLP-1 medications produce meaningful weight loss in most people who tolerate them and stay on treatment — but response varies. A doctor will discuss realistic expectations during consultation. Individual results are not guaranteed.
Yes. Online consultations on Singapore-licensed telemedicine platforms can cover initial assessment, prescribing where appropriate, and ongoing follow-up. For complex medical situations, an in-person consultation may be the better starting point.
Expect SGD 450–1,100 per month for GLP-1 medication at maintenance dose in Singapore in 2026, depending on which drug, which dose, and which clinic. Add the consultation and any blood tests. Medisave and insurance coverage is limited for weight-management use. The cost question is real, but it's downstream of whether GLP-1 is clinically appropriate for you — which is the conversation worth having first.
To book a confidential weight-management consultation with a Singapore-licensed doctor on Noah, start the evaluation when you're ready.
For related reading, see our medical weight loss guide, our comparison of Ozempic and Mounjaro, and our hawker-food weight-loss guide.


Articles on Noah are for informational purposes only and do not replace medical advice from a qualified doctor. Pricing in this article reflects typical early-2026 ranges in Singapore and changes over time; check current pricing with the prescriber. GLP-1 medications are prescription-only and require a consultation with a Singapore-licensed doctor. To consult on Noah, click here.
Health Sciences Authority Singapore. Register of Therapeutic Products. (Link)
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384:989-1002.
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387:205-216.
Ministry of Health Singapore. Chronic Disease Management Programme (CDMP). (Link)